Le, X., Patel, J., Shum, E., Sanborn, R. E., Baik, C. S., Shu, C. A., Kim, C., Fidler, M. D., Hall, R., Hanna, N., Mohindra, N., Sabari, J. K., Heeke, S., Hernandez, M., Gray, J. E., Heymach, J. V., & Saltos, A. (2023). LBA71 A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naïve EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis). Annals of Oncology, 34, S1313–S1314. https://doi.org/10.1016/j.annonc.2023.10.072